{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "status": "retrieved", "company": "Infant Bacterial Therapeutics", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:07Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2026", "category": "Interimsrapport", "date": "2026-05-06", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b027354d8e44a5d55bc4685ce60a31680&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "IBT Delarsrapport Q1 2026 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/aab98738e2c5e633c3f51d1ff0cf52426", "final_url": "https://attachment.news.eu.nasdaq.com/aab98738e2c5e633c3f51d1ff0cf52426", "filename": "IBT_Delarsrapport_Q1_2026_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2026-q1\\IBT_Delarsrapport_Q1_2026_SWE.pdf", "content_type": "application/pdf", "size": 605339, "sha256": "60547f958272dd40ba2712e07317218b73088891e55b691618e32cfdcb697788", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2026-q1\\IBT_Delarsrapport_Q1_2026_SWE.pdf", "filename": "IBT_Delarsrapport_Q1_2026_SWE.pdf", "extension": ".pdf", "size": 605339, "sha256": "60547f958272dd40ba2712e07317218b73088891e55b691618e32cfdcb697788", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2026-q1\\extracted\\IBT_Delarsrapport_Q1_2026_SWE\\IBT_Delarsrapport_Q1_2026_SWE.txt", "text_chars": 25715, "metadata": { "page_count": 15, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2026-q1\\extracted\\IBT_Delarsrapport_Q1_2026_SWE\\IBT_Delarsrapport_Q1_2026_SWE.extraction.json" } } ], "announcement_id": "1440119", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:14Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB publicerar Årsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-03-27", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bb79125e01308503d8fb0682efb0e64c0&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "IBT AR 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8c22c84d7301089482c83358d64784a4", "final_url": "https://attachment.news.eu.nasdaq.com/a8c22c84d7301089482c83358d64784a4", "filename": "IBT_AR_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-annual\\IBT_AR_2025_SWE.pdf", "content_type": "application/pdf", "size": 1492882, "sha256": "57d5849913dcb69ecf4754806e59c338a346dfc9a40e3c06e522c8255e4d9c1a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-annual\\IBT_AR_2025_SWE.pdf", "filename": "IBT_AR_2025_SWE.pdf", "extension": ".pdf", "size": 1492882, "sha256": "57d5849913dcb69ecf4754806e59c338a346dfc9a40e3c06e522c8255e4d9c1a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-annual\\extracted\\IBT_AR_2025_SWE\\IBT_AR_2025_SWE.txt", "text_chars": 126960, "metadata": { "page_count": 66, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-annual\\extracted\\IBT_AR_2025_SWE\\IBT_AR_2025_SWE.extraction.json" } } ], "announcement_id": "1429445", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:17Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari - 31 december 2025", "category": "Bokslutskommuniké", "date": "2026-02-06", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b000eddc922590847a6e3ee0d56221b3f&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "IBT Bokslutskommunike Q4 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a66490c3b1577450316a0e9ff1c7f1af0", "final_url": "https://attachment.news.eu.nasdaq.com/a66490c3b1577450316a0e9ff1c7f1af0", "filename": "IBT_Bokslutskommunike_Q4_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q4\\IBT_Bokslutskommunike_Q4_2025_SWE.pdf", "content_type": "application/pdf", "size": 1899480, "sha256": "f0075fd94502b2a6d54a9ec3f7ad5ee50db8f09da508060f5cb663e1959987e9", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q4\\IBT_Bokslutskommunike_Q4_2025_SWE.pdf", "filename": "IBT_Bokslutskommunike_Q4_2025_SWE.pdf", "extension": ".pdf", "size": 1899480, "sha256": "f0075fd94502b2a6d54a9ec3f7ad5ee50db8f09da508060f5cb663e1959987e9", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q4\\extracted\\IBT_Bokslutskommunike_Q4_2025_SWE\\IBT_Bokslutskommunike_Q4_2025_SWE.txt", "text_chars": 23017, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q4\\extracted\\IBT_Bokslutskommunike_Q4_2025_SWE\\IBT_Bokslutskommunike_Q4_2025_SWE.extraction.json" } } ], "announcement_id": "1418379", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:23Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 30 september 2025", "category": "Interimsrapport", "date": "2025-11-13", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=bc6cede42db1d7a976b2e88e76bbfd15a&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "IBT Delarsrapport Q3 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a917c68d40817e6683d3ddbe39cc8ede0", "final_url": "https://attachment.news.eu.nasdaq.com/a917c68d40817e6683d3ddbe39cc8ede0", "filename": "IBT_Delarsrapport_Q3_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q3\\IBT_Delarsrapport_Q3_2025_SWE.pdf", "content_type": "application/pdf", "size": 616826, "sha256": "eff505bc2ee8be453261fe103f9076d941f5b9abd186965a5e2d4bdc2dac5505", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q3\\IBT_Delarsrapport_Q3_2025_SWE.pdf", "filename": "IBT_Delarsrapport_Q3_2025_SWE.pdf", "extension": ".pdf", "size": 616826, "sha256": "eff505bc2ee8be453261fe103f9076d941f5b9abd186965a5e2d4bdc2dac5505", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q3\\extracted\\IBT_Delarsrapport_Q3_2025_SWE\\IBT_Delarsrapport_Q3_2025_SWE.txt", "text_chars": 28703, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q3\\extracted\\IBT_Delarsrapport_Q3_2025_SWE\\IBT_Delarsrapport_Q3_2025_SWE.extraction.json" } } ], "announcement_id": "1400340", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:27Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 30 juni 2025", "category": "Halvårsrapport", "date": "2025-08-20", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3b6d7c8e695faa8f16d807ea4db5b340&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "IBT Delarsrapport Q2 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a1b435d92c4f4ae2608ff1bc2cd7539a3", "final_url": "https://attachment.news.eu.nasdaq.com/a1b435d92c4f4ae2608ff1bc2cd7539a3", "filename": "IBT_Delarsrapport_Q2_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q2\\IBT_Delarsrapport_Q2_2025_SWE.pdf", "content_type": "application/pdf", "size": 600031, "sha256": "cb1be1894b069461b3f76ae27243aa2c1e06a97909be21597672f49f865e7cbd", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q2\\IBT_Delarsrapport_Q2_2025_SWE.pdf", "filename": "IBT_Delarsrapport_Q2_2025_SWE.pdf", "extension": ".pdf", "size": 600031, "sha256": "cb1be1894b069461b3f76ae27243aa2c1e06a97909be21597672f49f865e7cbd", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q2\\extracted\\IBT_Delarsrapport_Q2_2025_SWE\\IBT_Delarsrapport_Q2_2025_SWE.txt", "text_chars": 29386, "metadata": { "page_count": 15, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q2\\extracted\\IBT_Delarsrapport_Q2_2025_SWE\\IBT_Delarsrapport_Q2_2025_SWE.extraction.json" } } ], "announcement_id": "1384191", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:31Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2025", "category": "Interimsrapport", "date": "2025-05-07", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7812a17f37d874ba0372929cb127d527&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "IBT Delarsrapport Q1 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a697a551aa54bc2748df37c10092bee28", "final_url": "https://attachment.news.eu.nasdaq.com/a697a551aa54bc2748df37c10092bee28", "filename": "IBT_Delarsrapport_Q1_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q1\\IBT_Delarsrapport_Q1_2025_SWE.pdf", "content_type": "application/pdf", "size": 563292, "sha256": "254e2c7f46096af3ba99a4b04ad8190770155a87929019b5f91f29ad23f09e0e", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q1\\IBT_Delarsrapport_Q1_2025_SWE.pdf", "filename": "IBT_Delarsrapport_Q1_2025_SWE.pdf", "extension": ".pdf", "size": 563292, "sha256": "254e2c7f46096af3ba99a4b04ad8190770155a87929019b5f91f29ad23f09e0e", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\IBT_Delarsrapport_Q1_2025_SWE\\IBT_Delarsrapport_Q1_2025_SWE.txt", "text_chars": 23394, "metadata": { "page_count": 14, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\IBT_Delarsrapport_Q1_2025_SWE\\IBT_Delarsrapport_Q1_2025_SWE.extraction.json" } } ], "announcement_id": "1361488", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:39Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB publicerar Årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-03-27", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bdada50e058b5762e4fb9f8442f6ecf8a&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "IBT AR 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a6f888496f180b76dd578e4bec19c9ca5", "final_url": "https://attachment.news.eu.nasdaq.com/a6f888496f180b76dd578e4bec19c9ca5", "filename": "IBT_AR_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-annual\\IBT_AR_2024_SWE.pdf", "content_type": "application/pdf", "size": 1875625, "sha256": "e8ac50795bc8b094a5d257f04dfc2fd0ebaaa24f3678d4f1bf48188dc98dccbc", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-annual\\IBT_AR_2024_SWE.pdf", "filename": "IBT_AR_2024_SWE.pdf", "extension": ".pdf", "size": 1875625, "sha256": "e8ac50795bc8b094a5d257f04dfc2fd0ebaaa24f3678d4f1bf48188dc98dccbc", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-annual\\extracted\\IBT_AR_2024_SWE\\IBT_AR_2024_SWE.txt", "text_chars": 128182, "metadata": { "page_count": 68, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-annual\\extracted\\IBT_AR_2024_SWE\\IBT_AR_2024_SWE.extraction.json" } } ], "announcement_id": "1351572", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:41Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari - 31 december 2024", "category": "Bokslutskommuniké", "date": "2025-02-13", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b219653b47b21d8d37022e6efc14f4497&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "IBT Bokslutskommunike 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a75ff970d41a7f900c40093f0e44f40ca", "final_url": "https://attachment.news.eu.nasdaq.com/a75ff970d41a7f900c40093f0e44f40ca", "filename": "IBT_Bokslutskommunike_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q4\\IBT_Bokslutskommunike_2024_SWE.pdf", "content_type": "application/pdf", "size": 591673, "sha256": "60673f59815137502ce0484f4dff8728d5b74a7739ce3cc53291776654892714", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q4\\IBT_Bokslutskommunike_2024_SWE.pdf", "filename": "IBT_Bokslutskommunike_2024_SWE.pdf", "extension": ".pdf", "size": 591673, "sha256": "60673f59815137502ce0484f4dff8728d5b74a7739ce3cc53291776654892714", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q4\\extracted\\IBT_Bokslutskommunike_2024_SWE\\IBT_Bokslutskommunike_2024_SWE.txt", "text_chars": 28388, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q4\\extracted\\IBT_Bokslutskommunike_2024_SWE\\IBT_Bokslutskommunike_2024_SWE.extraction.json" } } ], "announcement_id": "1342722", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:47Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 30 september 2024", "category": "Interimsrapport", "date": "2024-11-14", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=be2a184557531627f12b4c743e4162be9&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "IBT Q3 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac8f2b73a9b8bf06d95baa057ee338fc3", "final_url": "https://attachment.news.eu.nasdaq.com/ac8f2b73a9b8bf06d95baa057ee338fc3", "filename": "IBT_Q3_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q3\\IBT_Q3_2024_SWE.pdf", "content_type": "application/pdf", "size": 1033437, "sha256": "8fa6fb15345a38a89d633e003181c4d9316286be92b6fe92e2ee91ea19dfdb52", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q3\\IBT_Q3_2024_SWE.pdf", "filename": "IBT_Q3_2024_SWE.pdf", "extension": ".pdf", "size": 1033437, "sha256": "8fa6fb15345a38a89d633e003181c4d9316286be92b6fe92e2ee91ea19dfdb52", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q3\\extracted\\IBT_Q3_2024_SWE\\IBT_Q3_2024_SWE.txt", "text_chars": 31917, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q3\\extracted\\IBT_Q3_2024_SWE\\IBT_Q3_2024_SWE.extraction.json" } } ], "announcement_id": "1327765", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:53Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 30 juni 2024", "category": "Halvårsrapport", "date": "2024-08-28", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b879b094182889bce0984b3e5d04e5f11&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "IBT Q2 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a0cc900329bea0b4d50080bd6355bda22", "final_url": "https://attachment.news.eu.nasdaq.com/a0cc900329bea0b4d50080bd6355bda22", "filename": "IBT_Q2_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q2\\IBT_Q2_2024_SWE.pdf", "content_type": "application/pdf", "size": 592214, "sha256": "828207bdc489450224f095a0e200679a215d28b9d73bdc3f17a46a77068ee59b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q2\\IBT_Q2_2024_SWE.pdf", "filename": "IBT_Q2_2024_SWE.pdf", "extension": ".pdf", "size": 592214, "sha256": "828207bdc489450224f095a0e200679a215d28b9d73bdc3f17a46a77068ee59b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q2\\extracted\\IBT_Q2_2024_SWE\\IBT_Q2_2024_SWE.txt", "text_chars": 30065, "metadata": { "page_count": 15, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q2\\extracted\\IBT_Q2_2024_SWE\\IBT_Q2_2024_SWE.extraction.json" } } ], "announcement_id": "1313235", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:14:59Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2024", "category": "Interimsrapport", "date": "2024-05-07", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7d0f45700fa593a9e0b100e952ba66f4&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "IBT Q1 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/af20d6c8b8ab9d41a8631f94b247f5b51", "final_url": "https://attachment.news.eu.nasdaq.com/af20d6c8b8ab9d41a8631f94b247f5b51", "filename": "IBT_Q1_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q1\\IBT_Q1_2024_SWE.pdf", "content_type": "application/pdf", "size": 587652, "sha256": "6ed837bdc6bdb7a412198cd615dc48f759cf9381b4e368d1d10d666e84a49bc1", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q1\\IBT_Q1_2024_SWE.pdf", "filename": "IBT_Q1_2024_SWE.pdf", "extension": ".pdf", "size": 587652, "sha256": "6ed837bdc6bdb7a412198cd615dc48f759cf9381b4e368d1d10d666e84a49bc1", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q1\\extracted\\IBT_Q1_2024_SWE\\IBT_Q1_2024_SWE.txt", "text_chars": 27735, "metadata": { "page_count": 14, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2024-q1\\extracted\\IBT_Q1_2024_SWE\\IBT_Q1_2024_SWE.extraction.json" } } ], "announcement_id": "1294105", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:15:06Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB publicerar Årsredovisning för räkenskapsåret 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-03-25", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba67f73ce2150c6f2b071c09711935ca8&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "IBT Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a83118a0ffca658a51b7661b06f9d367b", "final_url": "https://attachment.news.eu.nasdaq.com/a83118a0ffca658a51b7661b06f9d367b", "filename": "IBT_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-annual\\IBT_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 2041275, "sha256": "e0e4c6cdf0708d6b045abc77f70fe01082123b17c52426cdd1cd9b385347ca0c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-annual\\IBT_Arsredovisning_2023.pdf", "filename": "IBT_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 2041275, "sha256": "e0e4c6cdf0708d6b045abc77f70fe01082123b17c52426cdd1cd9b385347ca0c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-annual\\extracted\\IBT_Arsredovisning_2023\\IBT_Arsredovisning_2023.txt", "text_chars": 143392, "metadata": { "page_count": 73, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-annual\\extracted\\IBT_Arsredovisning_2023\\IBT_Arsredovisning_2023.extraction.json" } } ], "announcement_id": "1283683", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:15:08Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ), Bokslutskommuniké 1 januari - 31 December 2023", "category": "Bokslutskommuniké", "date": "2024-02-08", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2c256b9cecd4622a19b3fb7f0696c6e7&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "IBT Bokslutskommumike 2023 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a32e4c171dc57857ab695a042d279a1ad", "final_url": "https://attachment.news.eu.nasdaq.com/a32e4c171dc57857ab695a042d279a1ad", "filename": "IBT_Bokslutskommumike_2023_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q4\\IBT_Bokslutskommumike_2023_SWE.pdf", "content_type": "application/pdf", "size": 617492, "sha256": "0d62610a160ae9194d24a678fc256c4156241f31155955b7ddd6ebee83312994", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q4\\IBT_Bokslutskommumike_2023_SWE.pdf", "filename": "IBT_Bokslutskommumike_2023_SWE.pdf", "extension": ".pdf", "size": 617492, "sha256": "0d62610a160ae9194d24a678fc256c4156241f31155955b7ddd6ebee83312994", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q4\\extracted\\IBT_Bokslutskommumike_2023_SWE\\IBT_Bokslutskommumike_2023_SWE.txt", "text_chars": 36086, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q4\\extracted\\IBT_Bokslutskommumike_2023_SWE\\IBT_Bokslutskommumike_2023_SWE.extraction.json" } } ], "announcement_id": "1273533", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:15:14Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 30 September 2023", "category": "Interimsrapport", "date": "2023-11-10", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7670857707eac3635c8c61428b078d49&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "IBT Q3 2023 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/acbf891c15f9e41312f319d0ddc1594b3", "final_url": "https://attachment.news.eu.nasdaq.com/acbf891c15f9e41312f319d0ddc1594b3", "filename": "IBT_Q3_2023_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q3\\IBT_Q3_2023_SWE.pdf", "content_type": "application/pdf", "size": 647867, "sha256": "f05f5d227315ed3ee516f2036ecf70a3ffbd03bf221bb18effe2dd19f6987e40", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q3\\IBT_Q3_2023_SWE.pdf", "filename": "IBT_Q3_2023_SWE.pdf", "extension": ".pdf", "size": 647867, "sha256": "f05f5d227315ed3ee516f2036ecf70a3ffbd03bf221bb18effe2dd19f6987e40", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q3\\extracted\\IBT_Q3_2023_SWE\\IBT_Q3_2023_SWE.txt", "text_chars": 39437, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q3\\extracted\\IBT_Q3_2023_SWE\\IBT_Q3_2023_SWE.extraction.json" } } ], "announcement_id": "1258557", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:15:19Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 30 juni 2023", "category": "Halvårsrapport", "date": "2023-08-25", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b40d0cf9c5bfd2045fc4f738fb5be832e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "IBT Q2 2023 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ab00cd4908db4148bfe82b553f3543eba", "final_url": "https://attachment.news.eu.nasdaq.com/ab00cd4908db4148bfe82b553f3543eba", "filename": "IBT_Q2_2023_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q2\\IBT_Q2_2023_SWE.pdf", "content_type": "application/pdf", "size": 608750, "sha256": "4dfb488ba5020d824c3e34b05c4e7f98e2e5239bdfc522ec7c0276ecec505a8a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q2\\IBT_Q2_2023_SWE.pdf", "filename": "IBT_Q2_2023_SWE.pdf", "extension": ".pdf", "size": 608750, "sha256": "4dfb488ba5020d824c3e34b05c4e7f98e2e5239bdfc522ec7c0276ecec505a8a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q2\\extracted\\IBT_Q2_2023_SWE\\IBT_Q2_2023_SWE.txt", "text_chars": 35246, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q2\\extracted\\IBT_Q2_2023_SWE\\IBT_Q2_2023_SWE.extraction.json" } } ], "announcement_id": "1244507", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:15:24Z", "company": "Infant Bacterial Therapeutics", "title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 31 mars 2023", "category": "Interimsrapport", "date": "2023-05-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf428a2811566892e1897cbddae12e0ec&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "IBT Q1 2023 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae1ad6598b6277e4600d2810e334d2c8f", "final_url": "https://attachment.news.eu.nasdaq.com/ae1ad6598b6277e4600d2810e334d2c8f", "filename": "IBT_Q1_2023_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q1\\IBT_Q1_2023_SWE.pdf", "content_type": "application/pdf", "size": 651935, "sha256": "ab30a5ae58ec8f12c3625d739c21cd62e25f33078af1b4aba15c0931ed6806bc", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q1\\IBT_Q1_2023_SWE.pdf", "filename": "IBT_Q1_2023_SWE.pdf", "extension": ".pdf", "size": 651935, "sha256": "ab30a5ae58ec8f12c3625d739c21cd62e25f33078af1b4aba15c0931ed6806bc", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q1\\extracted\\IBT_Q1_2023_SWE\\IBT_Q1_2023_SWE.txt", "text_chars": 28232, "metadata": { "page_count": 15, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\infant-bacterial-therapeutics\\nasdaq-reports\\reports\\2023-q1\\extracted\\IBT_Q1_2023_SWE\\IBT_Q1_2023_SWE.extraction.json" } } ], "announcement_id": "1226215", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "dfeca50851a75e20b3a9a859a52b5f5b0250b74832728988625ffd772bc5babb" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 92, "new_rows": 92, "total_count": null, "from_cache": false, "body_sha256": "83939576a3fc99055546bf34088a3fcc272db93504556f8fbf0f31b0810a58ce" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=192&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 192, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e5508a7f1b6f8d7742cd5b91568c5953e22f7de6610e54f3d300d35a378573ae" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 7, "new_rows": 7, "total_count": null, "from_cache": false, "body_sha256": "dd4b7319cf776e39a26bcc71ee9c2ec6f913efba41e9f09a4cbe13ff7ca7c8b6" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=7&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 7, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e47c2958927474c5024570b9522c21d79d7a42c4dafa8f9263473af76e0881fa" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "646e4dbba44c775e70a8a2280ad92c61c4bccbadd2110b01583df7b85c8d3ec4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 92, "new_rows": 92, "total_count": null, "from_cache": false, "body_sha256": "499fa75d74e5e9b5af9aaa79e93fea597844fc66f47163edc79a27e140ed8645" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=192&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 192, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e5508a7f1b6f8d7742cd5b91568c5953e22f7de6610e54f3d300d35a378573ae" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 4, "new_rows": 4, "total_count": null, "from_cache": false, "body_sha256": "9d6dde9654e10672a28cded5ccf9873dfed4aae603437cb07394737f2d3fd599" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Infant+Bacterial+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=4&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 4, "pagination": "row-offset", "query_text": "Infant Bacterial Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e27b60cb74ad0e336cee9c3aa3436314395a27959baa132e37b1113a29192eb8" } ], "identity": { "slug": "", "instrument_id": "TX2023390", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/ibt-b?id=TX2023390" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Infant Bacterial Therapeutics", "retrieved_at": "2026-08-07T04:15:24Z" }